Form 4: CRISPR Therapeutics GC Granted 16,500 Stock Options

CRISPR Therapeutics' General Counsel and Secretary, James R. Kasinger, was granted 16,500 stock options with an exercise price of $67.74, vesting over 48 months.

Summary

• James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG, reported an acquisition of derivative securities.
• The transaction involved the grant of 16,500 stock options (right to buy) on October 3, 2025.
• The exercise price for these options is $67.74 per common share.
• The options have an expiration date of October 3, 2035.
• The shares underlying the option will vest 100% in 48 equal monthly installments, with the first vesting date on November 3, 2025.
• Following this transaction, Mr. Kasinger beneficially owns 16,500 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive event, as it aligns management's financial interests with the company's long-term performance and shareholder value. It is a routine compensation practice and does not indicate any immediate operational or financial changes, hence a moderately positive score.

Positives

• The grant of stock options aligns the interests of the General Counsel and Secretary with those of the shareholders, incentivizing long-term performance.
• The vesting schedule over 48 months promotes executive retention and commitment to the company's future success.

Future Outlook

The vesting schedule of the stock options over 48 equal monthly installments indicates a long-term incentive structure designed to retain the General Counsel and align his performance with the company's sustained growth.

Industry Context

This is a routine executive compensation event, common across the biotechnology and pharmaceutical industries to incentivize long-term performance and retain key talent. Stock option grants are a standard component of executive pay packages, linking executive wealth to shareholder value creation.

Stakeholder Impact

• Shareholders: The grant of options aims to align executive incentives with shareholder returns, potentially leading to better long-term performance.
• Employees: This transaction specifically impacts a key executive, reinforcing the company's compensation strategy for leadership.

Next Steps

• The stock options will begin vesting in 48 equal monthly installments starting November 3, 2025.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction involving the grant of stock options as part of executive compensation. While it positively aligns management's interests with shareholders, it does not provide new fundamental information or significant operational updates that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals.

Keywords

CRISPR Therapeutics, CRSP, Stock Option, Insider Transaction, Form 4, Executive Compensation, James R. Kasinger